Producing MSC-derived cell therapies: workflows, technologies, and case studies

In this expert roundtable, four highly experienced industry professionals discuss key considerations in mesenchymal stem (or stromal) cell (MSC) manufacturing, including reagent selection, dosing, delivery methods, and final product formulation. The panelists also explore emerging modalities such as induced pluripotent stem cell (iPSC)-derived MSCs, gene-engineered MSCs, and exosome-based therapies, and emphasize the need for cost reduction and scalable manufacturing to improve accessibility and clinical success.